Lipha acamprosate for alcohol dependence
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee will review Lipha Pharmaceutical's NDA for acamprosate as maintenance therapy for alcohol abstinence on May 1